Zobrazeno 1 - 10
of 115
pro vyhledávání: '"Noriyoshi, Iriyama"'
Autor:
Hiroshi Ureshino, Yusuke Takeda, Kazuharu Kamachi, Takaaki Ono, Noriyoshi Iriyama, Eiichi Ohtsuka, Emiko Sakaida, Shinya Kimura
Publikováno v:
Clinics and Practice, Vol 14, Iss 4, Pp 1216-1224 (2024)
Background: ABL1 tyrosine kinase inhibitor discontinuation securely became among the therapeutic goal for chronic myeloid leukemia chronic phase patients (CML-CP). To establish successful prognostic factors for treatment-free remission (TFR), it is n
Externí odkaz:
https://doaj.org/article/de4999a41aa641b1965b3a4c3d7098b2
Autor:
Yuriko Nishiyama-Fujita, Tomonori Nakazato, Noriyoshi Iriyama, Michihide Tokuhira, Maho Ishikawa, Eriko Sato, Tomoiku Takaku, Keiji Sugimoto, Hiroyuki Fujita, Isao Fujioka, Shun Tsuchiya, Yuta Kimura, Eisaku Iwanaga, Norio Komatsu, Norio Asou, Masahiro Kizaki, Yoshihiro Hatta, Tatsuya Kawaguchi
Publikováno v:
Annals of Medicine, Vol 54, Iss 1, Pp 1244-1254 (2022)
Introduction Few studies have reported the outcomes of adolescents and young adults (AYAs) with chronic-phase chronic myeloid leukaemia (CML-CP) on tyrosine kinase inhibitors (TKIs).Materials and methods We retrospectively analysed the clinical featu
Externí odkaz:
https://doaj.org/article/2e6495f34fd84e83afef69bd99b33b59
Autor:
Hironao Nukariya, Katsuhiro Miura, Hiromichi Takahashi, Masaru Nakagawa, Takashi Hamada, Shun Ito, Takashi Ichinohe, Endo Toshihide, Kazuya Kurhihara, Takashi Koike, Kazuhide Iizuka, Shimon Ohtake, Noriyoshi Iriyama, Yoshihiro Hatta, Hideki Nakamura
Publikováno v:
HemaSphere, Vol 7, p e46165d9 (2023)
Externí odkaz:
https://doaj.org/article/634a53927e2642eb85ba46a2fdd64ae0
Autor:
Hiromichi Takahashi, Haruna Nishimaki, Yoko Nakanishi, Takashi Hamada, Masaru Nakagawa, Kazuhide Iizuka, Yoshihito Uchino, Noriyoshi Iriyama, Katsuhiro Miura, Tomohiro Nakayama, Shinobu Masuda, Yoshihiro Hatta, Hideki Nakamura
Publikováno v:
eJHaem, Vol 3, Iss 2, Pp 467-470 (2022)
Abstract Intravascular large B‐cell lymphoma (IVLBCL) is a rare subtype of B‐cell lymphoma characterized by aggressive disease progression with a high incidence of central nervous system (CNS) involvement. We retrospectively analyzed 16 patients
Externí odkaz:
https://doaj.org/article/9f2e963170604de98bcb6ef288e60b92
Autor:
Yuichi Ishikawa, Naomi Kawashima, Yoshiko Atsuta, Isamu Sugiura, Masashi Sawa, Nobuaki Dobashi, Hisayuki Yokoyama, Noriko Doki, Akihiro Tomita, Toru Kiguchi, Shiro Koh, Heiwa Kanamori, Noriyoshi Iriyama, Akio Kohno, Yukiyoshi Moriuchi, Noboru Asada, Daiki Hirano, Kazuto Togitani, Toru Sakura, Maki Hagihara, Tatsuki Tomikawa, Yasuhisa Yokoyama, Norio Asou, Shigeki Ohtake, Itaru Matsumura, Yasushi Miyazaki, Tomoki Naoe, Hitoshi Kiyoi
Publikováno v:
Blood Advances, Vol 4, Iss 1, Pp 66-75 (2020)
Abstract: The prognostic impact of KIT mutation on core-binding factor acute myeloid leukemia (CBF-AML) remains controversial. We registered 199 newly diagnosed de novo CBF-AML patients, aged 16 to 64 years, who achieved complete remission. They rece
Externí odkaz:
https://doaj.org/article/d8f98219f90f425d95e4fd4f64876f2b
Autor:
Noriyoshi Iriyama
Publikováno v:
Journal of Nihon University Medical Association. 81:193-196
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fca0cd56c49efb6c90459d225dcb7017
https://doi.org/10.4264/numa.81.4_193
https://doi.org/10.4264/numa.81.4_193
Autor:
Michihide Tokuhira, Yuta Kimura, Takayuki Tabayashi, Naoki Watanabe, Shun Tsuchiya, Tomoiku Takaku, Noriyoshi Iriyama, Eriko Sato, Tomonori Nakazato, Toru Mitsumori, Maho Ishikawa, Hiroyuki Fujita, Masahiro Kizaki, Miki Ando, Yoshihiro Hatta, Eisaku Iwanaga, Tatsuya Kawaguchi
Publikováno v:
International Journal of Hematology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4348e931da8d4acb898ea11cdf8aec40
https://doi.org/10.1007/s12185-023-03606-x
https://doi.org/10.1007/s12185-023-03606-x
Autor:
Katsuhiro Miura, Hiromichi Takahashi, Masaru Nakagawa, Takashi Hamada, Yoshihito Uchino, Kazuhide Iizuka, Shimon Ohtake, Noriyoshi Iriyama, Yoshihiro Hatta, Hideki Nakamura
Publikováno v:
Expert Review of Anticancer Therapy. 22:583-595
The standard of care for diffuse large B-cell lymphoma (DLBCL) is rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, its ideal dose intensity varies among cases.This review provides the latest insights on the dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa18cec00079bfd7c6e18326d1166d1e
https://doi.org/10.1080/14737140.2022.2071262
https://doi.org/10.1080/14737140.2022.2071262
Autor:
Shun Tsuchiya, Tomoiku Takaku, Naoki Watanabe, Noriyoshi Iriyama, Yuta Kimura, Eisaku Iwanaga, Kei-ji Sugimoto, Toru Mitsumori, Maho Ishikawa, Tomonori Nakazato, Hiroyuki Fujita, Eriko Sato, Yoshihiro Hatta, Norio Asou, Masahiro Kizaki, Michihide Tokuhira, Miki Ando, Tatsuya Kawaguchi
Publikováno v:
Internal Medicine; 2023, Vol. 62 Issue 22, p3299-3303, 5p
Publikováno v:
Cancer Medicine, Vol 5, Iss 11, Pp 3223-3234 (2016)
Abstract It has been shown that an increase in cytotoxic lymphocyte counts in the peripheral blood occurs rapidly after taking dasatinib, but the underlying mechanism is not yet elucidated. To investigate the influence of dasatinib on signal transduc
Externí odkaz:
https://doaj.org/article/7f488780737d469d9054bffe431e8a83